(Q38004063)

26 August 2017

title

β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review (English)

1 reference

26 August 2017

1 reference

1 reference

Mahipal G Sinnollareddy

Mahipal G Sinnollareddy

1

0 references

Jason A. Roberts

Jason A Roberts

4

0 references

Jeffrey Lipman

Jeffrey Lipman

3

0 references

Michael S. Roberts

Michael S Roberts

2

0 references

publication date

1 June 2012

1 reference

Clinical and Experimental Pharmacology and Physiology

26 August 2017

published in

1 reference

26 August 2017

volume

39

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

489-496

1 reference

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

The epidemiology of sepsis in the United States from 1979 through 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Sepsis in European intensive care units: results of the SOAP study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

International study of the prevalence and outcomes of infection in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Pharmacokinetic issues for antibiotics in the critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Augmented renal clearance in the Intensive Care Unit: an illustrative case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Augmented renal clearance: implications for antibacterial dosing in the critically ill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Antibiotic dosing in multiple organ dysfunction syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Continuous infusion of beta-lactams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Treatment of gram-negative bacillary septicemia with cefoperazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Pharmacodynamics of cefepime in patients with Gram-negative infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care u

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Retrospective review of neurotoxicity induced by cefepime and ceftazidime

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Neurotoxic effects associated with antibiotic use: management considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

The neurotoxicity and safety of treatment with cefepime in patients with renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Prospective monitoring of cefepime in intensive care unit adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Therapeutic drug monitoring of antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Daily serum piperacillin monitoring is advisable in critically ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Prospective determination of serum ceftazidime concentrations in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Adjustment of dosing of antimicrobial agents for bodyweight in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Antimicrobial dosing considerations in obese adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Antibiotic resistance--what's dosing got to do with it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Using PK/PD to optimize antibiotic dosing for critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Target concentration intervention: beyond Y2K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1681.2012.05715.X

10.1111/J.1440-1681.2012.05715.X

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference